Regulation of NF-kB by TCR and costimulatory signaling
TCR 和共刺激信号对 NF-kB 的调节
基本信息
- 批准号:8381804
- 负责人:
- 金额:$ 31.29万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:
- 资助国家:美国
- 起止时间:至 2014-08-31
- 项目状态:已结题
- 来源:
- 关键词:Antigen ReceptorsAntigensAutoimmunityBindingCD28 geneCalcium SignalingCell physiologyCellsCoiled-Coil DomainCollectionComplementary DNAComplexCuesCytoplasmic TailEngineeringEnhancersGoalsHumanImmuneImmune System DiseasesImmunologic SurveillanceKinesinKnock-in MouseLinkMAP3K7 geneMalignant NeoplasmsMediatingModelingMolecularMolecular TargetNF-kappa BOpen Reading FramesPathway interactionsPhasePhosphorylationPlayProteinsRNA InterferenceRecruitment ActivityRegulationRoleScreening procedureSignal PathwaySignal TransductionSignaling MoleculeSpleenStimulusStructureT-Cell ActivationT-Cell ProliferationT-LymphocyteTRAF6 geneTailTechnologyTestingWorkanergyarmbasecDNA Librarycaspase-8domain mappingexpression cloninggenome wide association studyimmunological synapseimmunological synapse formationinhibitor/antagonistinsightinterestmouse modelmutantnovelprogramsreconstitutionresponsescaffoldtherapy designtooltranscription factor
项目摘要
This Project will contribute to the overall goals of the Program by investigating the arm of TCR signaling that
activates NF-KB, a transcription factor that is required for antigen-induced T cell proliferation and activation.
The study of TCR signaling to NF-KB offers several opportunities to expand our understanding of how a T
cell interprets antigenic inputs. First, the mechanistic understanding of how the TCR activates NF-KB is far
from complete. Critical components of this pathway remain undiscovered and it is likely that new players in
this pathway will also play important roles in other arms of TCR signaling studied in the Program. In AIM 1,
we will use a novel expression cloning strategy to identify enhancers and suppressors of TCR signaling to
NF-KB. Second, maximal TCR-mediated NF-KB activation requires both TCR engagement by MHC plus
antigen (signal 1) and costimulatory signals (signal 2). In AIM 2, we will test the hypothesis that the CARD11-
GADS interaction is required for CD28-mediated costimulatory signaling to NF-KB. Third, while it is clear that
molecules that signal from the TCR to NF-KB are recruited to the immunological synapse (IS) in a dynamic,
regulated manner, it is unclear how and why this is precisely accomplished. In AIM 3, we will investigate how
NF-KB signaling intermediates are recruited to the immunological synapse. This project will benefit from
synergy with other projects in the Program. AIM 1 will use Core C and should yield novel components or
modulators of TCR signaling pathways that can be studied in Projects 1, 2, 3, and 4 for roles in TCR
clustering, Immunological Synapse (IS) formation and regulation, Sprouty!-mediated regulation, and calcium
signaling, respectively. AIM 2 may offer molecular insight into how a T cell makes the cellular choice of
activation or anergy, and will apply a mouse model and the expertise of J. Powell (Project 3). AIM 3 will use
Core B and technology developed by A. Kupfer (Project 2) and will contribute to the understanding of IS
formation and structure during T cell activation. Our results should add to the understanding of how the
molecular machinery of immune cells can recognize and interpret environmental cues, including pathogenic
and nonpathogenic stimuli, and respond appropriately. Since the inappropriate response to stimuli can result
in ineffective immune surveillance, autoimmunity, or cancer, our results may yield molecular targets for new
therapies designed to treat diseases of the immune system.
该项目将通过调查TCR信号的手臂来促进该计划的整体目标
激活NF-KB,这是抗原诱导的T细胞增殖和激活所需的转录因子。
对NF-KB的TCR信号的研究提供了一些机会,以扩大我们对T的理解
细胞解释抗原输入。首先,对TCR如何激活NF-KB的机械理解远
从完成。该途径的关键组成部分仍未被发现,很可能是
该途径还将在该程序中研究的TCR信号的其他臂中扮演重要角色。在AIM 1中,
我们将使用一种新颖的表达克隆策略来识别TCR信号的增强子和抑制器
NF-KB。其次,最大的TCR介导的NF-KB激活需要MHC Plus的TCR参与
抗原(信号1)和共刺激信号(信号2)。在AIM 2中,我们将测试Card11-的假设
GADS相互作用是CD28介导的对NF-KB的共刺激信号传导所必需的。第三,虽然很明显
从TCR到NF-KB信号的分子在动态中募集到免疫突触(IS)
受监管的方式,目前尚不清楚如何以及为什么要完成这项工作。在AIM 3中,我们将调查如何
NF-KB信号传导中间体被招募到免疫突触。这个项目将从
与该计划中的其他项目协同作用。 AIM 1将使用核心C,并应产生新颖的组件或
在项目1、2、3和4中可以研究的TCR信号通路的调节器
聚类,免疫突触(IS)形成和调节,发芽!介导的调节和钙
信号分别。 AIM 2可以提供分子洞察T细胞如何使细胞选择的细胞选择
激活或反对意见,并将应用鼠标模型和J. Powell的专业知识(项目3)。 AIM 3将使用
核心B和A. Kupfer(项目2)开发的技术,将有助于理解IS
T细胞激活过程中的形成和结构。我们的结果应该增加对如何
免疫细胞的分子机制可以识别和解释环境线索,包括致病性
和非致病性刺激,并做出适当的反应。由于对刺激的不适当反应会导致
在无效的免疫监测,自身免疫性或癌症中,我们的结果可能会产生新的分子靶标
旨在治疗免疫系统疾病的疗法。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Joel L Pomerantz其他文献
Joel L Pomerantz的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Joel L Pomerantz', 18)}}的其他基金
Targeting a Membrane Protease that Controls NK Cell Maturation
靶向控制 NK 细胞成熟的膜蛋白酶
- 批准号:
10631217 - 财政年份:2022
- 资助金额:
$ 31.29万 - 项目类别:
Targeting a Membrane Protease that Controls NK Cell Maturation
靶向控制 NK 细胞成熟的膜蛋白酶
- 批准号:
10506509 - 财政年份:2022
- 资助金额:
$ 31.29万 - 项目类别:
Mechanisms of Control of Lymphocyte Activation and Proliferation by a Critical Signaling Integrator
关键信号整合器控制淋巴细胞激活和增殖的机制
- 批准号:
10063977 - 财政年份:2019
- 资助金额:
$ 31.29万 - 项目类别:
Mechanisms of Control of Lymphocyte Activation and Proliferation by a Critical Signaling Integrator
关键信号整合器控制淋巴细胞激活和增殖的机制
- 批准号:
10528445 - 财政年份:2019
- 资助金额:
$ 31.29万 - 项目类别:
Mechanisms of Control of Lymphocyte Activation and Proliferation by a Critical Signaling Integrator
关键信号整合器控制淋巴细胞激活和增殖的机制
- 批准号:
10304147 - 财政年份:2019
- 资助金额:
$ 31.29万 - 项目类别:
Regulation of CARD11 signaling in normal and dysregulated lymphocyte development
CARD11 信号在正常和失调淋巴细胞发育中的调节
- 批准号:
8704412 - 财政年份:2013
- 资助金额:
$ 31.29万 - 项目类别:
Regulation of CARD11 signaling in normal and dysregulated lymphocyte development
CARD11 信号在正常和失调淋巴细胞发育中的调节
- 批准号:
9056446 - 财政年份:2013
- 资助金额:
$ 31.29万 - 项目类别:
Regulation of CARD11 signaling in normal and dysregulated lymphocyte development
CARD11 信号在正常和失调淋巴细胞发育中的调节
- 批准号:
8829795 - 财政年份:2013
- 资助金额:
$ 31.29万 - 项目类别:
Regulation of CARD11 signaling in normal and dysregulated lymphocyte development
CARD11 信号在正常和失调淋巴细胞发育中的调节
- 批准号:
8554256 - 财政年份:2013
- 资助金额:
$ 31.29万 - 项目类别:
Motor protein regulation of T cell receptor signaling
T 细胞受体信号传导的运动蛋白调节
- 批准号:
8099462 - 财政年份:2009
- 资助金额:
$ 31.29万 - 项目类别:
相似国自然基金
基于表达MHC-肽嵌合抗原受体T细胞治疗自身免疫疾病的策略和机制研究
- 批准号:81901643
- 批准年份:2019
- 资助金额:21.0 万元
- 项目类别:青年科学基金项目
特异性乙酰胆碱能受体嵌合抗原受体T细胞(AChR-CAR T)治疗实验性自身免疫性重症肌无力鼠模型的有效性和机制研究
- 批准号:81870988
- 批准年份:2018
- 资助金额:56.0 万元
- 项目类别:面上项目
滤泡辅助性T细胞在CTLA-4Ig诱导Graves病免疫耐受中的作用及机制研究
- 批准号:81801621
- 批准年份:2018
- 资助金额:21.0 万元
- 项目类别:青年科学基金项目
SOX1参与副肿瘤性抗GABABR脑炎抗原表达机制的研究
- 批准号:81771313
- 批准年份:2017
- 资助金额:54.0 万元
- 项目类别:面上项目
I型主要组织相容性复合体参与1型糖尿病异常自身抗原呈递的机制研究
- 批准号:81700691
- 批准年份:2017
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Comprehensive characterization of immune signaling networks in single-cells by joint quantification of proteins, protein complexes and mRNA
通过蛋白质、蛋白质复合物和 mRNA 的联合定量来全面表征单细胞中的免疫信号网络
- 批准号:
10636695 - 财政年份:2023
- 资助金额:
$ 31.29万 - 项目类别:
The role of SH2B3 in regulating CD8 T cells in Type 1 Diabetes
SH2B3 在 1 型糖尿病中调节 CD8 T 细胞的作用
- 批准号:
10574346 - 财政年份:2023
- 资助金额:
$ 31.29万 - 项目类别:
Determining the role of oxysterols in lymphocyte homing to lymph nodes in homeostasis and inflammation
确定氧甾醇在淋巴细胞归巢至淋巴结的稳态和炎症中的作用
- 批准号:
10677408 - 财政年份:2023
- 资助金额:
$ 31.29万 - 项目类别:
Engineering mono-fucosylated IgGs to fine-tune antibody-mediated effector functions
工程化单岩藻糖基化 IgG 来微调抗体介导的效应功能
- 批准号:
10647938 - 财政年份:2023
- 资助金额:
$ 31.29万 - 项目类别:
Basic and Translational Mechanisms of Alloimmunization to RBC Transfusion. Project 2
红细胞输注同种免疫的基本和转化机制。
- 批准号:
10711669 - 财政年份:2023
- 资助金额:
$ 31.29万 - 项目类别: